ME03776B - Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze - Google Patents

Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze

Info

Publication number: ME03776B
Authority: ME; Montenegro
Prior art keywords: pyridin; isocitrate dehydrogenase; dehydrogenase inhibitors; quinolinone derivatives; quinolinone
Prior art date: 2014-09-19

Application number

MEP-2020-78A

Other languages

German (de)

English (en)

French (fr)

Inventor

Susan Ashwell

Ann-Marie Campbell

Justin Andrew Caravella

R Bruce Diebold

Anna Ericsson

Gary Gustafson

Jian Lin

Wei Lu

Zhongguo Wang

David R Lancia Jr

Original Assignee

Forma Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-19

Filing date

2015-09-18

Publication date

2021-04-20

2015-09-18 Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc

2021-04-20 Publication of ME03776B publication Critical patent/ME03776B/me

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

MEP-2020-78A 2014-09-19 2015-09-18 Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze ME03776B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201462053006P	2014-09-19	2014-09-19
US201562128089P	2015-03-04	2015-03-04
US201562150812P	2015-04-21	2015-04-21
EP18198969.0A EP3447050B1 (en)	2014-09-19	2015-09-18	Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (1)

Publication Number	Publication Date
ME03776B true ME03776B (me)	2021-04-20

Family

ID=54291606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2020-78A ME03776B (me)	2014-09-19	2015-09-18	Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze

Country Status (37)

Country	Link
US (8)	US9834539B2 (me)
EP (4)	EP4257131A3 (me)
JP (1)	JP6648115B2 (me)
KR (1)	KR102209667B1 (me)
CN (3)	CN107001328B (me)
AU (3)	AU2015317329B2 (me)
BR (1)	BR112017005238B1 (me)
CA (1)	CA2961817C (me)
CL (1)	CL2017000658A1 (me)
CO (1)	CO2017003241A2 (me)
CY (2)	CY1121149T1 (me)
DK (2)	DK3447050T3 (me)
EA (1)	EA034336B1 (me)
EC (1)	ECSP17022933A (me)
ES (3)	ES2790640T3 (me)
FI (1)	FI3733662T3 (me)
HR (1)	HRP20200666T1 (me)
HU (2)	HUE062424T2 (me)
IL (3)	IL292608B2 (me)
LT (2)	LT3194376T (me)
MA (2)	MA53352A (me)
ME (1)	ME03776B (me)
MX (2)	MX2017003404A (me)
MY (2)	MY176250A (me)
NZ (1)	NZ730373A (me)
PE (1)	PE20171056A1 (me)
PH (1)	PH12017500517B1 (me)
PL (3)	PL3733662T3 (me)
PT (3)	PT3194376T (me)
RS (2)	RS60140B1 (me)
SA (1)	SA517381129B1 (me)
SG (1)	SG11201702194SA (me)
SI (2)	SI3194376T1 (me)
SM (2)	SMT202000212T1 (me)
TW (1)	TWI686390B (me)
WO (1)	WO2016044789A1 (me)
ZA (3)	ZA201702127B (me)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2740424T3 (es)	2009-03-13	2020-02-05	Agios Pharmaceuticals Inc	Métodos y composiciones para trastornos relacionados con la proliferación celular
ES2594402T3 (es) *	2009-10-21	2016-12-20	Agios Pharmaceuticals, Inc.	Métodos y composiciones para trastornos relacionados con la proliferación celular
MX2020001236A (es)	2014-02-06	2022-06-30	Heptares Therapeutics Ltd	Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
TWI686390B (zh)	2014-09-19	2020-03-01	美商弗瑪治療公司	作為突變型異檸檬酸去氫酶抑制劑的吡啶-2(1h)-酮喹啉酮衍生物
US10350206B2 (en)	2014-09-19	2019-07-16	Bayer Pharma Aktiengesellschaft	Benzyl substituted indazoles as BUB1 inhibitors
WO2016044787A1 (en)	2014-09-19	2016-03-24	Forma Therapeutics, Inc.	Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2768694T3 (es)	2014-09-19	2020-06-23	Forma Therapeutics Inc	Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
ES2706888T3 (es)	2014-09-19	2019-04-01	Forma Therapeutics Inc	Referencia cruzada a aplicaciones relacionadas
EP3237385B1 (en) *	2014-12-22	2021-11-24	The United States of America, as represented by The Secretary, Department of Health and Human Services	Mutant idh1 inhibitors useful for treating cancer
WO2016171756A1 (en)	2015-04-21	2016-10-27	Forma Therapeutics, Inc.	Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en)	2015-04-21	2019-05-21	Forma Tm2, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN119285538A (zh)	2017-05-04	2025-01-10	发现号收购集团	作为例如用于保护植物的害虫防治剂的2-{[2-(苯氧基甲基)吡啶-5-基]氧基}乙胺衍生物及相关化合物
US11013733B2 (en) *	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2020232381A1 (en)	2019-05-16	2020-11-19	Forma Therapeutics, Inc.	INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
PT3720442T (pt) *	2018-05-16	2023-03-13	Forma Therapeutics Inc	Inibição de idh-1 mutante
RS64069B1 (sr)	2018-05-16	2023-04-28	Forma Therapeutics Inc	Inhibicija mutiranog idh-1
US11311527B2 (en)	2018-05-16	2022-04-26	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10532047B2 (en)	2018-05-16	2020-01-14	Forma Therapeutics, Inc.	Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
TW202104207A (zh) *	2019-04-17	2021-02-01	美商健生生物科技公司	二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) *	2019-11-20	2023-01-31	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) *	2020-10-27	2022-06-03	浙江工业大学	2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) *	2020-10-27	2022-07-29	浙江工业大学	一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) *	2022-12-28	2023-09-19	北京康立生医药技术开发有限公司	一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99731A0 (en)	1990-10-18	1992-08-18	Merck & Co Inc	Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en)	1992-10-30	1993-11-16	Octamer, Inc.	Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en)	2000-04-27	2003-06-05	Susan Beth Sobolov-Jaynes	Substituted benzolactam compounds
CA2488635C (en)	2002-06-12	2012-10-23	Abbott Laboratories	Antagonists of melanin concentrating hormone receptor
WO2004043936A1 (ja)	2002-11-14	2004-05-27	Kyowa Hakko Kogyo Co., Ltd.	Ｐｌｋ阻害剤
RU2284325C2 (ru) *	2003-12-17	2006-09-27	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
JPWO2005095382A1 (ja)	2004-03-30	2007-08-16	協和醗酵工業株式会社	抗腫瘍剤
WO2006054912A1 (fr) *	2004-11-18	2006-05-26	Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim'	Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en)	2006-02-24	2008-01-16	Kalypsys Inc	Quinolones useful as inducible nitric oxide synthase inhibitors
EP2044068A4 (en) *	2006-07-17	2010-07-21	Merck Sharp & Dohme	1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs
JP2010043004A (ja)	2006-12-06	2010-02-25	Dainippon Sumitomo Pharma Co Ltd	新規２環性複素環化合物
PT2152676E (pt)	2007-04-30	2013-06-25	Prometic Biosciences Inc	Derivados de triazina, composições contendo tais derivados, e métodos de tratamento do cancro e de doenças autoimunes usando tais derivados
BRPI1010881A2 (pt)	2009-06-08	2016-05-31	California Capital Equity Llc	derivados de triazina e suas aplicações terapêuticas.
EP2509600B1 (en)	2009-12-09	2017-08-02	Agios Pharmaceuticals, Inc.	Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012006104A2 (en)	2010-06-28	2012-01-12	Academia Sinica, Taiwan	Compounds and methods for treating tuberculosis infection
CN102558049B (zh) *	2010-12-17	2015-02-04	中国科学院上海药物研究所	一类双香豆素类化合物及其制备方法和用途
US20120184548A1 (en)	2011-01-19	2012-07-19	Romyr Dominique	Carboxylic acid aryl amides
US20120184562A1 (en)	2011-01-19	2012-07-19	Kin-Chun Luk	1,6- and 1,8-naphthyridines
US9464065B2 (en)	2011-03-24	2016-10-11	The Scripps Research Institute	Compounds and methods for inducing chondrogenesis
CN102827170A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
CN103814020B (zh) *	2011-06-17	2017-07-14	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
PH12014500682A1 (en)	2011-09-27	2014-05-12	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
KR102097343B1 (ko)	2011-12-21	2020-04-07	더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트	RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
HUE038403T2 (hu) *	2012-01-06	2018-10-29	Agios Pharmaceuticals Inc	Terápiásan alkalmazható vegyületek és alkalmazási módszereik
BR112015022483A2 (pt) *	2013-03-14	2017-07-18	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2015003146A1 (en)	2013-07-03	2015-01-08	Georgetown University	Boronic acid derivatives of resveratrol for activating deacetylase enzymes
PE20170143A1 (es)	2014-02-11	2017-03-19	Bayer Pharma AG	Benzimidazol-2-aminas como inhibidores de midh1
WO2016044787A1 (en)	2014-09-19	2016-03-24	Forma Therapeutics, Inc.	Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2706888T3 (es)	2014-09-19	2019-04-01	Forma Therapeutics Inc	Referencia cruzada a aplicaciones relacionadas
ES2768694T3 (es)	2014-09-19	2020-06-23	Forma Therapeutics Inc	Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
TWI686390B (zh)	2014-09-19	2020-03-01	美商弗瑪治療公司	作為突變型異檸檬酸去氫酶抑制劑的吡啶-2(1h)-酮喹啉酮衍生物
EP3237385B1 (en)	2014-12-22	2021-11-24	The United States of America, as represented by The Secretary, Department of Health and Human Services	Mutant idh1 inhibitors useful for treating cancer
GB2533925A (en)	2014-12-31	2016-07-13	Univ Bath	Antimicrobial compounds, compositions and methods
US10294206B2 (en)	2015-04-21	2019-05-21	Forma Tm2, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en)	2015-04-21	2016-10-27	Forma Therapeutics, Inc.	Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en)	2015-07-27	2019-10-30	Eli Lilly and Company	7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
MX2018010261A (es)	2016-02-26	2019-02-11	Agios Pharmaceuticals Inc	Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
US10696665B2 (en)	2016-06-06	2020-06-30	Eli Lilly And Company	Mutant IDH1 inhibitors
US10836759B2 (en)	2016-06-22	2020-11-17	The University Of North Carolina At Chapel Hill	Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
NZ754115A (en)	2016-12-16	2021-07-30	Lilly Co Eli	7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

2015
- 2015-09-18 TW TW104131044A patent/TWI686390B/zh active
- 2015-09-18 EA EA201790657A patent/EA034336B1/ru unknown
- 2015-09-18 EP EP23176702.1A patent/EP4257131A3/en active Pending
- 2015-09-18 JP JP2017515059A patent/JP6648115B2/ja active Active
- 2015-09-18 EP EP15778433.1A patent/EP3194376B1/en active Active
- 2015-09-18 DK DK18198969.0T patent/DK3447050T3/da active
- 2015-09-18 MY MYPI2017700895A patent/MY176250A/en unknown
- 2015-09-18 ES ES18198969T patent/ES2790640T3/es active Active
- 2015-09-18 PT PT15778433T patent/PT3194376T/pt unknown
- 2015-09-18 CN CN201580050441.5A patent/CN107001328B/zh active Active
- 2015-09-18 PH PH1/2017/500517A patent/PH12017500517B1/en unknown
- 2015-09-18 LT LTEP15778433.1T patent/LT3194376T/lt unknown
- 2015-09-18 US US14/858,167 patent/US9834539B2/en active Active
- 2015-09-18 HU HUE20157755A patent/HUE062424T2/hu unknown
- 2015-09-18 IL IL292608A patent/IL292608B2/en unknown
- 2015-09-18 EP EP20157755.8A patent/EP3733662B1/en active Active
- 2015-09-18 LT LTEP18198969.0T patent/LT3447050T/lt unknown
- 2015-09-18 EP EP18198969.0A patent/EP3447050B1/en active Active
- 2015-09-18 BR BR112017005238-5A patent/BR112017005238B1/pt active IP Right Grant
- 2015-09-18 CA CA2961817A patent/CA2961817C/en active Active
- 2015-09-18 ME MEP-2020-78A patent/ME03776B/me unknown
- 2015-09-18 PL PL20157755.8T patent/PL3733662T3/pl unknown
- 2015-09-18 KR KR1020177010585A patent/KR102209667B1/ko active IP Right Grant
- 2015-09-18 MX MX2017003404A patent/MX2017003404A/es active IP Right Grant
- 2015-09-18 DK DK15778433.1T patent/DK3194376T3/en active
- 2015-09-18 MY MYPI2020001463A patent/MY197533A/en unknown
- 2015-09-18 ES ES15778433T patent/ES2704897T3/es active Active
- 2015-09-18 PT PT201577558T patent/PT3733662T/pt unknown
- 2015-09-18 SG SG11201702194SA patent/SG11201702194SA/en unknown
- 2015-09-18 SM SM20200212T patent/SMT202000212T1/it unknown
- 2015-09-18 MA MA053352A patent/MA53352A/fr unknown
- 2015-09-18 AU AU2015317329A patent/AU2015317329B2/en active Active
- 2015-09-18 RS RS20200418A patent/RS60140B1/sr unknown
- 2015-09-18 MA MA040481A patent/MA40481A/fr unknown
- 2015-09-18 WO PCT/US2015/051055 patent/WO2016044789A1/en active Application Filing
- 2015-09-18 SI SI201530537T patent/SI3194376T1/sl unknown
- 2015-09-18 CN CN202010391529.6A patent/CN111909130B/zh active Active
- 2015-09-18 PT PT181989690T patent/PT3447050T/pt unknown
- 2015-09-18 PE PE2017000471A patent/PE20171056A1/es unknown
- 2015-09-18 PL PL18198969T patent/PL3447050T3/pl unknown
- 2015-09-18 PL PL15778433T patent/PL3194376T3/pl unknown
- 2015-09-18 HU HUE15778433A patent/HUE041460T2/hu unknown
- 2015-09-18 ES ES20157755T patent/ES2953347T3/es active Active
- 2015-09-18 RS RS20181586A patent/RS58184B1/sr unknown
- 2015-09-18 SI SI201531117T patent/SI3447050T1/sl unknown
- 2015-09-18 FI FIEP20157755.8T patent/FI3733662T3/fi active
- 2015-09-18 CN CN202311265288.0A patent/CN117695280A/zh active Pending
- 2015-09-18 NZ NZ73037315A patent/NZ730373A/en unknown
- 2015-09-18 SM SM20190018T patent/SMT201900018T1/it unknown
2017
- 2017-03-07 US US15/452,256 patent/US20170174658A1/en not_active Abandoned
- 2017-03-14 IL IL251163A patent/IL251163B/en active IP Right Grant
- 2017-03-15 MX MX2019013203A patent/MX2019013203A/es unknown
- 2017-03-17 CL CL2017000658A patent/CL2017000658A1/es unknown
- 2017-03-19 SA SA517381129A patent/SA517381129B1/ar unknown
- 2017-03-27 ZA ZA2017/02127A patent/ZA201702127B/en unknown
- 2017-04-03 CO CONC2017/0003241A patent/CO2017003241A2/es unknown
- 2017-04-13 EC ECIEPI201722933A patent/ECSP17022933A/es unknown
2018
- 2018-04-27 US US15/964,844 patent/US10414752B2/en active Active
2019
- 2019-01-21 CY CY20191100075T patent/CY1121149T1/el unknown
- 2019-03-01 US US16/290,240 patent/US10550098B2/en active Active
- 2019-04-17 ZA ZA2019/02446A patent/ZA201902446B/en unknown
- 2019-12-12 US US16/712,951 patent/US10889567B2/en active Active
- 2019-12-16 AU AU2019283765A patent/AU2019283765B2/en active Active
2020
- 2020-04-24 HR HRP20200666TT patent/HRP20200666T1/hr unknown
- 2020-05-04 CY CY20201100407T patent/CY1122865T1/el unknown
- 2020-11-23 US US17/101,018 patent/US11498913B2/en active Active
2021
- 2021-04-18 IL IL282363A patent/IL282363B/en unknown
- 2021-08-10 AU AU2021215141A patent/AU2021215141B2/en active Active
2022
- 2022-11-09 US US17/984,069 patent/US20230125739A1/en not_active Abandoned
2023
- 2023-04-14 ZA ZA2023/04409A patent/ZA202304409B/en unknown
- 2023-11-09 US US18/506,060 patent/US20240150319A1/en active Pending

Also Published As

Publication number	Publication date
CY1122865T1 (el)	2021-05-05
EP3733662A1 (en)	2020-11-04
KR102209667B1 (ko)	2021-01-29
EP3447050B1 (en)	2020-02-19
HUE062424T2 (hu)	2023-11-28
MY197533A (en)	2023-06-21
CN107001328B (zh)	2020-06-05
US20180312487A1 (en)	2018-11-01
EP3733662B1 (en)	2023-06-07
SMT201900018T1 (it)	2019-02-28
EP4257131A2 (en)	2023-10-11
US10414752B2 (en)	2019-09-17
DK3447050T3 (da)	2020-03-09
MY176250A (en)	2020-07-24
ZA202304409B (en)	2024-08-28
EP3194376B1 (en)	2018-10-24
CY1121149T1 (el)	2020-05-29
CN111909130B (zh)	2023-10-31
IL282363B (en)	2022-06-01
EA201790657A1 (ru)	2017-08-31
PH12017500517B1 (en)	2022-08-03
AU2019283765A1 (en)	2020-01-16
EA201790657A8 (ru)	2018-02-28
FI3733662T3 (fi)	2023-08-09
SA517381129B1 (ar)	2021-04-26
DK3194376T3 (en)	2019-01-21
ES2704897T3 (es)	2019-03-20
PH12017500517A1 (en)	2017-08-07
AU2015317329B2 (en)	2019-10-31
US10889567B2 (en)	2021-01-12
CL2017000658A1 (es)	2017-12-22
AU2019283765B2 (en)	2021-05-13
EP3194376A1 (en)	2017-07-26
US9834539B2 (en)	2017-12-05
IL292608B2 (en)	2024-10-01
PL3733662T3 (pl)	2024-01-22
US20200223822A1 (en)	2020-07-16
ES2953347T3 (es)	2023-11-10
BR112017005238B1 (pt)	2023-01-17
ZA201702127B (en)	2019-06-26
ES2790640T3 (es)	2020-10-28
EP4257131A3 (en)	2024-01-10
IL251163A0 (en)	2017-04-30
PE20171056A1 (es)	2017-07-21
US20240150319A1 (en)	2024-05-09
EP3447050A1 (en)	2019-02-27
IL251163B (en)	2021-05-31
AU2015317329A1 (en)	2017-04-27
US20190263778A1 (en)	2019-08-29
US10550098B2 (en)	2020-02-04
JP2017528487A (ja)	2017-09-28
MX2019013203A (es)	2020-01-20
MX2017003404A (es)	2017-07-28
PT3447050T (pt)	2020-09-17
AU2021215141A1 (en)	2021-09-02
CA2961817A1 (en)	2016-03-24
CN117695280A (zh)	2024-03-15
RS60140B1 (sr)	2020-05-29
KR20170063742A (ko)	2017-06-08
MA53352A (fr)	2021-09-15
MA40481A (fr)	2017-07-26
IL292608A (en)	2022-07-01
CO2017003241A2 (es)	2017-09-20
BR112017005238A2 (pt)	2017-12-19
SI3194376T1 (sl)	2019-03-29
JP6648115B2 (ja)	2020-02-14
US20230125739A1 (en)	2023-04-27
IL282363A (en)	2021-06-30
HUE041460T2 (hu)	2019-05-28
US20160083366A1 (en)	2016-03-24
LT3194376T (lt)	2019-02-25
CN111909130A (zh)	2020-11-10
US20170174658A1 (en)	2017-06-22
RS58184B1 (sr)	2019-03-29
TW201617335A (zh)	2016-05-16
PT3194376T (pt)	2019-02-04
PT3733662T (pt)	2023-08-18
ECSP17022933A (es)	2017-08-31
PL3447050T3 (pl)	2020-07-27
US20210078973A1 (en)	2021-03-18
EA034336B1 (ru)	2020-01-29
WO2016044789A1 (en)	2016-03-24
SG11201702194SA (en)	2017-04-27
IL292608B1 (en)	2024-06-01
AU2021215141B2 (en)	2023-10-19
CA2961817C (en)	2024-03-12
PL3194376T3 (pl)	2019-05-31
SMT202000212T1 (it)	2020-05-08
NZ758641A (en)	2023-12-22
US11498913B2 (en)	2022-11-15
HRP20200666T1 (hr)	2020-07-24
ZA201902446B (en)	2023-12-20
CN107001328A (zh)	2017-08-01
SI3447050T1 (sl)	2020-08-31
NZ730373A (en)	2019-11-29
LT3447050T (lt)	2020-05-11
TWI686390B (zh)	2020-03-01

Publication	Publication Date	Title
ME03776B (me)	2021-04-20	Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze
MA47123A (fr)	2021-03-17	Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA47125A (fr)	2021-04-28	Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA41140A (fr)	2017-10-17	Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
ME03574B (me)	2020-07-20	Heteroarilna jedinjenja koja su korisna kao inhibitori sumoaktivirajućeg enzima
MA45189A (fr)	2019-04-10	Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA45244A (fr)	2019-04-17	Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
CL2016002736A1 (es)	2017-06-23	Inhibidores de demetilasa-1 específico de lisina
MA40943A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3416964A4 (en)	2019-09-18	Carboxamide derivatives as RSK inhibitors
MA54567A (fr)	2021-10-27	Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
ME03723B (me)	2021-04-20	2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
MA46878A (fr)	2019-10-02	Composés de benzodiazolium en tant qu'inhibiteurs d'enac
DK3202766T3 (da)	2020-03-23	Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor
IL250038A0 (en)	2017-03-30	4,5 - dehydroisoxazole derivatives used as nampt inhibitors
LT3445743T (lt)	2021-09-27	Aminorūgšties darinio provaistas
EP2953470A4 (en)	2016-08-03	2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
FR3023290B1 (fr)	2016-08-19	Derives de flavaglines
MA41174A (fr)	2017-10-25	Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
LT3319970T (lt)	2019-11-11	Pirido-oksazinono dariniai kaip tnap inhibitoriai